Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Cumberland Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda Cumberland Pharmaceuticals için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.6%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Mar 07

Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares

Jan 09

Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S

Oct 02

Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?

Nov 09

We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation

Apr 21

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?

Feb 13

One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts

Nov 19

Cumberland Pharmaceuticals Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Cumberland Pharmaceuticals yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:CPIX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	38	-10	-1	-1	N/A
3/31/2024	39	-8	5	5	N/A
12/31/2023	40	-6	6	6	N/A
9/30/2023	39	-2	7	9	N/A
6/30/2023	41	-2	8	10	N/A
3/31/2023	40	-4	5	7	N/A
12/31/2022	42	-6	6	8	N/A
9/30/2022	41	-7	6	7	N/A
6/30/2022	38	-9	4	4	N/A
3/31/2022	37	-7	4	4	N/A
12/31/2021	36	-6	6	6	N/A
9/30/2021	38	-3	5	5	N/A
6/30/2021	39	-3	5	6	N/A
3/31/2021	40	-5	5	6	N/A
12/31/2020	37	-7	3	5	N/A
9/30/2020	36	-8	3	5	N/A
6/30/2020	34	-10	4	5	N/A
3/31/2020	34	-10	3	4	N/A
12/31/2019	34	-9	2	3	N/A
9/30/2019	39	-8	3	6	N/A
6/30/2019	40	-6	0	4	N/A
3/31/2019	41	-6	-2	2	N/A
12/31/2018	29	-11	-1	3	N/A
9/30/2018	39	-6	-3	-1	N/A
6/30/2018	42	-5	0	2	N/A
3/31/2018	40	-9	N/A	-2	N/A
12/31/2017	41	-8	N/A	-1	N/A
9/30/2017	39	-8	N/A	1	N/A
6/30/2017	36	-7	N/A	0	N/A
3/31/2017	35	-2	N/A	1	N/A
12/31/2016	33	-1	N/A	1	N/A
9/30/2016	32	0	N/A	1	N/A
6/30/2016	31	0	N/A	1	N/A
3/31/2016	33	0	N/A	4	N/A
12/31/2015	34	1	N/A	6	N/A
9/30/2015	35	1	N/A	7	N/A
6/30/2015	37	2	N/A	9	N/A
3/31/2015	37	2	N/A	8	N/A
12/31/2014	37	2	N/A	7	N/A
9/30/2014	36	0	N/A	4	N/A
6/30/2014	33	-1	N/A	1	N/A
3/31/2014	30	-3	N/A	0	N/A
12/31/2013	32	-2	N/A	1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CPIX 'un tahmini kazanç büyümesinin tasarruf oranının ( 2.5% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: CPIX 'un kazançlarının US pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: CPIX şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: CPIX şirketinin gelirinin US pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: CPIX şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CPIX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Cumberland Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus forecasts updated

Consensus EPS estimates increase to -US$0.18

Analysts update estimates

Analysts lower EPS estimates to -US$0.37

Recent updates

Second quarter 2024 earnings released: US$0.077 loss per share (vs US$0.061 profit in 2Q 2023)

Cumberland Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2023)

Cumberland Pharmaceuticals Inc. to Report Q1, 2024 Results on May 07, 2024

Cumberland Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $5.8 million.

New minor risk - Share price stability

Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 23, 2024

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Full year 2023 earnings released: US$0.44 loss per share (vs US$0.38 loss in FY 2022)

Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 05, 2024

Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.073 loss per share (vs US$0.028 loss in 3Q 2022)

Cumberland Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 07, 2023

Cumberland Pharmaceuticals Inc. Announces New Antimicrobial Agents and Chemotherapy Detaining the Results of the First Clinical Study Investigating the Safety and Pharmacokinetics of Vibativ®? Injection in Children 2 to 17 Years of Age

New minor risk - Share price stability

Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Second quarter 2023 earnings released: EPS: US$0.061 (vs US$0.091 loss in 2Q 2022)

Cumberland Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 08, 2023

Cumberland Pharmaceuticals Inc. Announces the Publication of Positive Results from Clinical Study Investigating the Safety and Pharmacokinetics of Caldolor in Newborn Infants, Published in the Journal Pediatric Drugs

Cumberland Pharmaceuticals Inc. Announces FDA Clearance of IND for New Treatment of Idiopathic Pulmonary Fibrosis

U.S. Food and Drug Administration Approves Cumberland Pharmaceuticals Inc.'s Expanded Lab Labulation for Caldolor

First quarter 2023 earnings released: EPS: US$0.013 (vs US$0.094 loss in 1Q 2022)

Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?

Full year 2022 earnings released: US$0.38 loss per share (vs US$0.37 loss in FY 2021)

Cumberland Pharmaceuticals Inc. Announces Demise of Joey A. Jacobs, Member of Board of Directors

Cumberland Pharmaceuticals Inc. Announces Approval of Supplemental New Drug Application from U.S. Food and Drug Administration

Third quarter 2022 earnings released: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021)

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Cumberland Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.091 loss per share (vs US$0.049 profit in 2Q 2021)

Cumberland Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 09, 2022

Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of Directors

Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)

Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of Directors

Cumberland Pharmaceuticals Inc. Announces Executive Changes

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cumberland Pharmaceuticals Inc. to Report Q1, 2022 Results on May 10, 2022

Insufficient new directors

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Tabuk and Cumberland Partner to Bring Innovative Antibiotic with Life-Saving Potential to Middle East

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2021 Results on Mar 08, 2022

Now 22% undervalued

Cumberland Pharmaceuticals Inc. (NasdaqGS:CPIX) acquired SANCUSO from Kyowa Kirin, Inc. for $17 million.

Checking In On Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. Receives FDA Approval for Expanded Labeling for Caldolor®

Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.083 loss in 3Q 2020)

Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?

Consensus forecasts updated

Second quarter 2021 earnings released: EPS US$0.049 (vs US$0.11 loss in 2Q 2020)

Cumberland Pharmaceuticals Inc.(NasdaqGS:CPIX) dropped from Russell Microcap Growth Index

Cumberland Pharmaceuticals Inc. Releases a Series of Case Reports Describing the Effectiveness of Vibativ® (Telavancin) in Treating Secondary Bacterial Infections in COVID-19 Patients

Consensus EPS estimates increase to -US$0.18

We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation

Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 27, 2021

Full year 2020 earnings released: US$0.43 loss per share (vs US$0.23 loss in FY 2019)

Revenue beats expectations

Cumberland Pharmaceuticals Inc. to Report Q4, 2020 Results on Mar 09, 2021

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?

New 90-day high: US$3.31

New 90-day high: US$3.22

Analysts update estimates

One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts

Cumberland Pharmaceuticals Inc. Announces the Launch of Reditrex® (Methotrexate) Injection

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.083 loss per share

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.083 loss per share